Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. New therapeutics for myelodysplastic syndromes

    ... the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these agents represent a significant ... the MDS clone:   The azanucleosides (azacitidine and decitabine) remain the best treatment option for many higher-risk MDS ...

    Research Review last updated 05/02/2016 - 9:28am.

  2. Clinical Trials Report for April 2016

    ... agent (HMA), azacitidine (AZA) or decitabine (DEC). This study is being conducted in IL, MD, NY, ...

    Page last updated 08/10/2016 - 11:00am.

  3. More is better: Combination therapies for myelodysplastic syndromes

    ... for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be effective in the treatment of ... an epigenetic approach, where one combines azacitidine or decitabine (the class of drugs known as hypomethylating agents) with a class of ...

    Research Review last updated 05/02/2016 - 9:14am.

  4. Options for MDS patients beyond HMAs

    ... or after a period of response. HMAs, azacytidine and decitabine , were approved for International Prognostic Scoring System ... mutant proteins, IDH2; and SGI-110, a combination between decitabine and and deoxyguanine, with promising responses. For now, however, ...

    Research Review last updated 05/02/2016 - 9:09am.

  5. Recent developments in myelodysplastic syndromes

    ... between the years 2004 – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these are curative.  In ... have consistently predicted response to azacitidine or decitabine.  -There are several novel agents and combinations of agents that ...

    Research Review last updated 05/02/2016 - 9:16am.

  6. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be effective in the treatment of ... responses to hypomethylating agents, such as azacitidine and decitabine. Splicing factor genes are mutated in about 50% of MDS patients ...

    Research Review last updated 05/02/2016 - 9:14am.

  7. Infections in myelodysplastic syndromes: a review

    ... use of DNA hypomethylating drugs (5-azacytidine and decitabine ) and lenalidomide in recent years for treating MDS has ... supportive care or low-dose cytarabine, those receiving decitabine had higher infection rates compared to those on supportive care. ...

    Research Review last updated 05/02/2016 - 9:28am.

  8. Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

    ... failed therapy with a hypomethylating agent (such as decitabine [Vidaza] and azacitidine [AZA]). ...

    Clinical Trial last updated 04/28/2016 - 12:21pm.

  9. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

    ... agent (HMA), azacitidine (AZA) or decitabine (DEC). Status:  ...

    Clinical Trial last updated 04/27/2016 - 12:49pm.

  10. Sapacitibine shows promise for high-risk MDS patients

    ... are azacitidine (5-AZA, Vidaza®) and decitabine (Dacogen®). Both of these drugs are hypomethylating agents, ...

    Research Review last updated 05/02/2016 - 9:30am.